A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Proliferative responses to HIV antigens are either absent or of small magnitude in HIV-infected patients, even in the early stages of infection when vigorous proliferative responses to recall antigens are still seen. Remune consists of an inactivated, gp120-depleted virus intended to stimulate HIV-specific immune responses. Remune has been reported to increase lymphocyte proliferative responses to HIV antigens in patients with high CD4 cell counts. Many other T-cell-dependent responses are also impaired in HIV-infected patients, such as after vaccination with hepatitis A or B vaccine. In th...

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients may be eligible for this study if they:
• • Have completed at least 60 weeks of treatment on ACTG 328.
• • Are willing to continue on their assigned ACTG 328 treatment until after they have completed 24 weeks on this substudy.
• • Have a viral load less than or equal to 2,000 copies/ml.
• • Exclusion Criteria
• Patients will not be eligible for this study if they:
• • Have an active opportunistic (HIV-related) infection.
• • Are pregnant or breast-feeding.
• • Have taken or are taking certain medications that are prohibited.

Trial Officials